{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-137930","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.685068+00:00","generated_at":"2026-05-15T08:04:00.461517+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Perspective Therapeutics updates corporate presentation; highlights 212Pb pipeline with Phase 1/2a data in 2026","bullets":["Phase 1/2a data for VMT-α-NET in neuroendocrine tumors shows durable disease control and best-in-class safety profile.","VMT01 (212Pb-MC1R) for melanoma shows preliminary anti-tumor activity and tolerability; combination with checkpoint inhibitors planned.","PSV359 targeting FAP-α for solid tumors demonstrates improved tumor retention; Phase 1/2a trial ongoing.","Phase 1/2 data expected across all three clinical programs in 2026.","Proprietary Pb-based chelator and Lead-212 isotope platform designed to optimize therapeutic index."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-137930","json":"https://secwatch.observer/filing/0001193125-26-137930.json","markdown":"https://secwatch.observer/filing/0001193125-26-137930.md","text":"https://secwatch.observer/filing/0001193125-26-137930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526137930/0001193125-26-137930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526137930/catx-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:04:00.461517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}